Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-16 5:36 pm Sale | 2025-10-15 | 13D | Keros Therapeutics, Inc. KROS | Pontifax Management 4 G.P. (2015) Ltd. | 0 0.000% | -4,787,331 (Position Closed) | Filing History |
| 2025-09-25 10:55 am Purchase | 2025-09-12 | 13D | LB Pharmaceuticals Inc Common Stock LBRX | Pontifax Management 4 G.P. (2015) Ltd. | 1,411,681 6.300% | 1,411,681 (New Position) | Filing History |
| 2025-09-18 09:26 am Purchase | 2024-06-27 | 13G | Climb Bio, Inc. CLYM | Pontifax Management 4 G.P. (2015) Ltd. | 5,206,380 7.700% | 5,206,380 (New Position) | Filing History |
| 2025-04-18 5:10 pm Purchase | 2025-04-17 | 13D | Keros Therapeutics, Inc. KROS | Pontifax Management 4 G.P. (2015) Ltd. | 4,787,331 11.800% | 52,824 (+1.12%) | Filing History |
| 2024-11-05 10:55 am Sale | 2024-09-30 | 13G | Nuvectis Pharma, Inc. NVCT | Pontifax Management 4 G.P. (2015) Ltd. | 288,873 1.500% | -628,527 (-68.51%) | Filing History |
| 2024-02-06 08:47 am Purchase | 2023-12-31 | 13G | Nuvectis Pharma, Inc. NVCT | Pontifax Management 4 G.P. (2015) Ltd. | 917,400 5.300% | 917,400 (New Position) | Filing History |